14.42
-0.01 (-0.07%)
| Previous Close | 14.43 |
| Open | 14.41 |
| Volume | 2,579,252 |
| Avg. Volume (3M) | 6,969,405 |
| Market Cap | 4,527,889,920 |
| Price / Earnings (Forward) | 30.49 |
| Price / Sales | 6.99 |
| Price / Book | 16.46 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Profit Margin | -5.41% |
| Operating Margin (TTM) | -6.35% |
| Diluted EPS (TTM) | -0.090 |
| Quarterly Revenue Growth (YOY) | 13.40% |
| Total Debt/Equity (MRQ) | 229.11% |
| Current Ratio (MRQ) | 3.34 |
| Operating Cash Flow (TTM) | 3.56 M |
| Levered Free Cash Flow (TTM) | 29.27 M |
| Return on Assets (TTM) | 3.95% |
| Return on Equity (TTM) | -18.12% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Amicus Therapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.13 |
|
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.72% |
| % Held by Institutions | 103.25% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 14.50 (Jefferies, 0.56%) | Hold |
| 14.50 (Leerink Partners, 0.56%) | Hold | |
| Median | 14.50 (0.56%) | |
| Average | 14.50 (0.56%) | |
| Total | 2 Hold | |
| Avg. Price @ Call | 14.26 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jefferies | 22 Jan 2026 | 14.50 (0.55%) | Hold | 14.27 |
| Leerink Partners | 29 Dec 2025 | 14.50 (0.55%) | Hold | 14.25 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |